638 COMMANDER-001: a phase 1/2, first-in-human, multicenter, open label study of SQZ-eAPC-HPV as monotherapy and with pembrolizumab in patients with HPV16+ recurrent, locally advanced, or metastatic solid tumors (trial in progress)
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.